Arteriovenous fistulae are artificial connections between the artery and vein in the arm which allow needles to be inserted for haemodialysising patients wit kidney failure. Occasionally severe debilitating pain can arise from these fistulae for which no cause can be found. Such pain can be very difficult to treat. Many commonly used used painkillers are known to cause significant side effects in patients with renal failure (drowsiness, confusion etc. Qutenza (topical capsaicin 8%) is a new treatment made from chilli peppers which is applied to the skin as a patch and works directly at the nerve endings in the skin to prevent pain. It therefore should not have the systemic side effects of other drugs. It has been demonstrated to be beneficial in other painful conditions for example post-shingles pain and nerve pain from HIV. It has never been used for critical ischaemia before. We propose to investigate the efficacy of Qutenza in treating patients with end stage renal failure and chronic pain from their fistulae (AVF). We will recruit 20 patients with painful AVF and treat them with Qutenza. We will follow them up for 12 weeks and monitor the change in their pain scores.
Study Type
OBSERVATIONAL
Enrollment
20
Transdermal patch
Department of Renal Surgery, Queen Elizabeth University Hospital
Glasgow, Lanarkshire, United Kingdom
RECRUITINGNeuropathic pain
As assessed by Visual Analogue Pain Score
Time frame: 12weeks
Neuropathic pain
As assessed by Visual Analogue Pain Score and Brief Pain Inventory
Time frame: 1 week, 6 weeks
Quality of life
As assessed by EQ-5D
Time frame: 6 weeks, 12 weeks
Safety and tolerability
As assessed by: Number of adverse reactions.
Time frame: 1 week, 6 weeks and 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.